Andrew Mumford is a leading global market access expert with a wealth of experience in launching new products in the rare disease sector. He is currently working as a Principal Consultant at Initiate, where he employs a solution-focused approach to consultancy services. Andrew has held various senior roles in pricing and reimbursement projects, HTA submissions, value dossier development, and value communication across global markets. His unique expertise extends to developing and implementing access initiatives ensuring clinical demand, value demonstration, and acceptance by the payer customer group independent of their market, dataset, and belief.

Andrew's academic background includes a Bachelor of Science in Chemistry from the University of Kent, along with certifications from the ABPI and IPHA. Besides, he has pursued the Six Sigma Master Black Belt course from Expert Rating Certified Professional. Professional experiences that Andrew has had include his role as Director of Market Access - CNS Europe at Otsuka Pharmaceutical Companies Europe, former General Manager for the UK and Ireland at Global Kinetics Corporation, and former National Market Access Manager at Quintiles. Andrew has also held healthcare development manager and senior medical representative roles at ProStrakan and Wyeth, respectively, among others.